The AVEN Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited human knockout cell population engineered to disrupt the AVEN gene in the A-549 lung carcinoma cell line. This polyclonal product comprises a heterogeneous mix of edited alleles, providing a robust loss-of-function model for investigating the apoptosis inhibitory role of AVEN without clonal selection artifacts. The CRISPR/Cas9-mediated gene disruption enables researchers to dissect AVEN-dependent signaling networks in a cellular context that retains native regulatory complexity, making it suitable for high-resolution mechanistic studies and functional genomics applications.
The host A-549 cell line, derived from the lung carcinoma tissue of a 58-year-old Caucasian male, is a widely used epithelial model that exhibits characteristics of alveolar type II pulmonary epithelium. A-549 cells are well-established in cancer biology and drug metabolism research, offering a physiologically relevant platform for studying lung adenocarcinoma and xenobiotic responses. Their adherent growth and stable karyotype facilitate reproducible experimentation in apoptosis, cell cycle, and DNA damage response assays.
AVEN encodes an anti-apoptotic protein that integrates signals from the intrinsic apoptotic pathway and cell cycle checkpoints. It functions by binding to BCL2L1 and APAF1, thereby inhibiting apoptosome formation and the subsequent activation of CASP9 and downstream executioner CASP3. AVEN also interacts with ATR to contribute to cell cycle checkpoint control, linking apoptosis regulation with genomic stability. Upstream, AVEN expression is regulated by the transcription factors E2F1 and TP53, positioning it at the intersection of proliferative signaling and p53-dependent apoptosis. Representative pathway components include APAF1, CYCS, CASP9, CASP3, and BCL2L1.
In the A-549 cellular background, disruption of AVEN is particularly significant for modeling lung adenocarcinoma and investigating mechanisms of chemoresistance. Because TP53 serves as an upstream regulator of AVEN and A-549 cells harbor a wild-type TP53 gene, this knockout model enables precise interrogation of p53-mediated apoptosis evasion strategies. The loss of AVEN function can sensitize cells to DNA-damaging agents and other pro-apoptotic stimuli, facilitating the study of tumor cell survival pathways and the identification of therapeutic vulnerabilities associated with apoptosis inhibition.
This AVEN knockout cell population supports a broad range of experimental applications, including apoptosis induction assays (e.g., Annexin V staining), caspase-3/9 activity measurements, and flow cytometric cell cycle analysis. It is also well-suited for co-immunoprecipitation studies to examine protein complexes involving APAF1 and BCL2L1, as well as western blotting for downstream effector caspases. Researchers can employ these cells to explore cancer drug resistance mechanisms, DNA damage signaling, and cell cycle checkpoint control. For additional details or custom requests, please contact Ascent Research.
